
Opinion|Videos|February 24, 2025
Current and Emerging Treatment Landscape of mHSPC
Jack Andrews MD; Eugene Cone, MD; and Arash Rezazadeh, MD, discuss how metastatic hormone-sensitive prostate cancer presents clinically, explore current treatment standards including combination therapies, evaluate emerging data from the ARANOTE trial on darolutamide efficacy, consider quality of life factors in treatment selection, and examine how novel therapeutic approaches may reshape future care pathways.
Advertisement
Timecodes
1:54 mHSPC and Imaging
4:57 Current SOC in mHSPC
10:15 Choosing Therapy in mHSPC
18:51 ARANOTE Trial in mHSPC
21:15 Experience With ARI
27:08 Emerging mHSPC Treatments
32:51 ARANOTE Subgroup Analysis
35:31 Future Outlook for mHSPC
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The ArteraAI Prostate Test: What It Is and How It Works
2
HHS requests testosterone therapy label updates, citing new safety data
3
Unmet needs and emerging solutions in MRI-guided prostate cancer care
4
Retrospective study suggests differences in OAB therapy persistence among older adults
5











